Redburn raised the price target for the Moderna Inc. (NASDAQ:MRNA) stock from ‘a Sell’ to ‘a Neutral’. The rating was released on February 01, 2023, according to finviz. The research report from BofA Securities has upgraded the stock from Underperform to Neutral, with a price target set at $180. The stock was initiated by UBS, who disclosed in a research note on January 21, 2023, to Neutral and set the price objective to $221. Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Moderna Inc.